FDA Accepts NDA Resubmission for Parkinson’s Drug Istradefylline: Kyowa Kirin

Kyowa Hakko Kirin said on April 4 that the US FDA has accepted for review the resubmitted new drug application (NDA) for its Parkinson’s treatment istradefylline, with a target action date set for August 27. The filing seeks the FDA...read more